|Dr. Michel Detheux||Pres, CEO & Director||833.75k||N/A||1966|
|Mr. Matthew Gall||Chief Financial Officer||628.45k||N/A||1977|
|Dr. Joanne Jenkins Lager M.D.||Chief Medical Officer||705.56k||N/A||1971|
|Mr. Matthew A. Call M.B.A.||Chief Operating Officer||N/A||N/A||1973|
|Mr. Ryan Baker||Head of Investor Relations||N/A||N/A||N/A|
|Mr. Philippe Brantegem||Vice-Pres of HR||N/A||N/A||N/A|
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
iTeos Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.